12th International p53 Workshop

描述（申请人提供）：p53肿瘤抑制蛋白在肿瘤抑制中起关键作用，是人类癌症中最常发生突变的基因。因此，在分子、细胞和组织水平上阐明野生型p53如何在正常细胞中起作用，或者突变型p53如何在肿瘤细胞中起作用，将为人类癌症的治疗和诊断提供重要而新颖的方法。国际p53研讨会不断吸引研究p53的科学家进行互动，讨论他们最新的科学发现并发起新的合作。这些会议对于促进p53领域的特殊活力是非常重要和有效的。第12届国际p53研讨会将于2004年11月6日至10日在新西兰达尼丁与奥塔哥大学合作的一个会议中心举行。这次选择会议地点是为了促进美国和欧洲科学界与包括日本、澳大利亚和新西兰在内的太平洋地区科学家之间的互动。组委会由会议召集人Antony Braithwaite博士（新西兰达尼丁奥塔哥大学）和Bruce博士组成

DESCRIPTION (provided by applicant): The p53 tumor suppressor protein plays pivotal roles in tumor suppression and its gene is the most frequently mutated in human cancers. Thus, elucidating at molecular, cell and organismal levels how wild-type p53 functions in normal cells, or how mutant p53 dysfunctions in tumor cells will yield important and novel therapeutic and diagnostic approaches to human cancer. The International p53 Workshops have continuously attracted scientists working on p53 to interact, discuss their latest scientific findings and initiate new collaborations. These meetings have been enormously important and effective for promoting the exceptional vigor of the p53 field. The 12th International p53 Workshop will be held November 6-10 2004 in Dunedin, New Zealand at a conference center associated with the University of Otago. The conference site was chosen this time to facilitate interactions between the US and European scientific communities with scientists from Pacific region including Japan, Australia and New Zealand. The organizing committee consists of the conference convener, Dr Antony Braithwaite (University of Otago, Dunedin, New Zealand) along with Dr Bruce Baguley, (Auckland Cancer Society Research Centre, Auckland, New Zealand), Dr Carlos Cordon-Cardo, (Memorial Sloan-Kettering Cancer Centre, New York, USA) Dr Curtis Harris (Laboratory of Human Carcinogenesis, Bethesda, USA), Dr David Lane (University of Dundee, Dundee, Scotland), Dr Martin Lavin (Queensland Institute Medical Research, Brisbane, Australia), Dr Arnold Levine, (Institute for Advanced Study, Princeton, USA), Dr Moshe Oren (Weizmann Institute of Science, Rehovot, Israel), Dr Carol Prives (Columbia University, New York, USA), Dr Roger Reddel (Children's Medial Research Institute, Sydney, Australia), Dr Varda Rotter (Weizmann Institute of Science, Rehovot,Israel), Dr Janice Royds (University of Otago, Dunedin, New Zealand), Dr Thierry Soussi (Institut Curie, Paris, France), Dr Yoichi Taya (National Cancer Centre Research Institute, Tokoyo, Japan) and Dr Thea Tisty (University of California, San Francisco, USA). The organizing committee has been successful in raising money for covering expenses of invited speakers. Funding is requested for expenses of US postdoctoral fellows and graduate students including women and underrepresented minorities and people with disabilities. This support will be crucial for a key mission of the Workshop, which is to support the science and training of future US leaders in the p53 and cancer research communities.